Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Inclusion Criteria: * Males or females aged more than 50 years * Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT * Exudation on SD-OCT scans defined by intraretinal cysts or subretinal fluid. * Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS) * Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus photographs of adequate quality Exclusion Criteria: * Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or periocular infection, Active intraocular inflammation or Hypersensitivity. * Any previous history of intravitreal injections in the study eye for exudative AMD * Any secondary chorioretinal anastomosis due to retinal scar or fibrosis * Any history of vitrectomy * Media opacities preventing accurate imaging of the retina (cataract) * Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane, macular hole) * Confirmed intraocular pressure ≥25 mmHg or non-stable glaucoma.